Overview
- Chinese health regulators have approved multiple brain‑computer interface products this year, most recently clearing an electrode‑cap system from Tiankai Suishi for clinical use.
- Tiankai Suishi’s device is a noninvasive cap studded with scalp electrodes that reads brain electrical signals and is being marketed to help doctors assess cognitive impairment.
- The Tiankai Suishi company was founded in 2023, lists about 10.67 million yuan in registered capital, and is led by Gu Bin, a Tianjin University medical‑school doctoral graduate.
- Beijing’s push pairs faster approvals with state and local financing and a surge of private investment to grow firms that could compete with overseas players such as Neuralink.
- Experts and U.S. analysts warn the push has wider consequences for patient privacy, research data access and national competition in bioscience as BCIs move from labs toward real patients.